We’re excited to attend an insightful PBBS seminar hosted by Dr. Brad Nelson, Scientific Director at the British Columbia Cancer Research Institute, on Deciphering and re-engineering the immune response to cancer. Join us in learning about the latest immunotherapies shaping the future of cancer research. Come meet our Biocytogen team to find out how we can support your drug development journey!
What is PBSS?
The Pharmaceutical and BioScience Society International (PBSS) is a non-profit organization of over 20,000 participants, within the biotechnology and pharmaceutical industries, working to promote the exchange of scientific ideas and provide new learning opportunities through educational and professional development events.
Event Overview
Date: May 22nd, 2026
Venue: Floral Hall at VanDusen Administration, 5251 Oak St, Vancouver, BC V6M 4H1, Canada
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Vancouver, Canada!
